| Field | Value |
|---|---|
| Trial Name | REACH3 |
| DOI | https://doi.org/10.1056/NEJMoa2033122 |
| Diagnosis | Chronic graft-versus-host disease, glucocorticoid-refractory or glucocorticoid-dependent |
| Drugs | Ruxolitinib 10 mg twice daily |
| Line Of Therapy | Second-line therapy |
| Regimen | Ruxolitinib at a dose of 10 mg twice daily compared with investigator's choice of therapy |
| Primary End Point | Overall response at week 24 |
| Secondary End Point | Failure-free survival and improved score on the modified Lee Symptom Scale at week 24 |
| Competitor Arm | Investigator's choice of therapy from a list of 10 commonly used options considered best available care |
| Efficacy | Overall response at week 24 was greater in the ruxolitinib group than in the control group (49.7% vs. 25.6%) |
| Response Types | Complete or partial response |
| Time To Response | |
| Surveillance | |
| Subsets | Patients 12 years of age or older with moderate or severe glucocorticoid-refractory or -dependent chronic GVHD |
| Adverse Events | Thrombocytopenia (15.2% in the ruxolitinib group and 10.1% in the control group) and anemia (12.7% and 7.6%, respectively) |
| Others | REACH3 ClinicalTrials.gov number, NCT03112603 |
| Conclusion | Ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response among patients with glucocorticoid-refractory or -dependent chronic GVHD. |